MCID: ADL008
MIFTS: 37

Adult Oligodendroglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adult Oligodendroglioma

MalaCards integrated aliases for Adult Oligodendroglioma:

Name: Adult Oligodendroglioma 12 15
Adult Brain Oligodendroglioma 12 73
Grade Ii Adult Oligodendroglial Tumor 12
Oligodendroglioma, Adult 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3186
MeSH 44 D009837
NCIt 50 C4014 C9376

Summaries for Adult Oligodendroglioma

MalaCards based summary : Adult Oligodendroglioma, also known as adult brain oligodendroglioma, is related to oligodendroglioma and pilomyxoid astrocytoma, and has symptoms including seizures and headache. An important gene associated with Adult Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Citrate cycle (TCA cycle) and Peroxisome. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and liver.

Related Diseases for Adult Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Adult Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 29.7 IDH1 IDH2
2 pilomyxoid astrocytoma 10.0 FGFR1 NF1
3 pilocytic astrocytoma 10.0 IDH1 NF1
4 nervous system cancer 9.9 IDH1 NF1
5 interval angle-closure glaucoma 9.9 IDH1 IDH2
6 enchondroma 9.9 IDH1 IDH2
7 intracranial chondrosarcoma 9.9 IDH1 IDH2
8 chondrosarcoma 9.9 IDH1 IDH2
9 cytogenetically normal acute myeloid leukemia 9.9 IDH1 IDH2
10 chondroblastic osteosarcoma 9.9 IDH1 IDH2
11 multiple enchondromatosis, maffucci type 9.9 IDH1 IDH2
12 intraductal papilloma 9.9 IDH1 IDH2
13 spindle cell hemangioma 9.9 IDH1 IDH2
14 periosteal chondrosarcoma 9.9 IDH1 IDH2
15 glioma susceptibility 1 9.9 IDH1 IDH2
16 adult astrocytic tumour 9.9 IDH1 IDH2
17 fibrillary astrocytoma 9.9 IDH1 IDH2
18 diffuse infiltrative lymphocytosis syndrome 9.9 IDH1 IDH2
19 drug-induced mental disorder 9.9 IDH1 IDH2
20 drug psychosis 9.9 IDH1 IDH2
21 astrocytoma 9.9 FGFR1 IDH1
22 undifferentiated pleomorphic sarcoma 9.9 IDH1 IDH2
23 2-hydroxyglutaric aciduria 9.9 IDH1 IDH2
24 bone marrow cancer 9.9 FGFR1 NF1
25 d-2-hydroxyglutaric aciduria 1 9.9 IDH1 IDH2
26 pineal parenchymal tumor of intermediate differentiation 9.9 IDH1 NF1
27 bile duct adenocarcinoma 9.9 IDH1 IDH2
28 enchondromatosis, multiple, ollier type 9.9 IDH1 IDH2
29 intrahepatic cholangiocarcinoma 9.9 IDH1 IDH2
30 cholangiocarcinoma 9.9 IDH1 IDH2
31 li-fraumeni syndrome 9.8 IDH1 NF1
32 giant cell glioblastoma 9.8 FGFR1 IDH1
33 gliosarcoma 9.8 FGFR1 IDH1
34 essential thrombocythemia 9.8 IDH1 IDH2
35 pilocytic astrocytoma of cerebellum 9.8 IDH1 IDH2 NF1
36 supratentorial cancer 9.8 IDH1 IDH2 NF1
37 cerebrum cancer 9.8 IDH1 IDH2 NF1
38 myelofibrosis 9.8 IDH1 IDH2
39 bladder urothelial carcinoma 9.8 FGFR1 IDH1
40 central nervous system cancer 9.8 IDH1 IDH2 NF1
41 brain cancer 9.7 IDH1 IDH2 NF1
42 brain stem glioma 9.7 FGFR1 IDH1 IDH2
43 myelodysplastic syndrome 9.7 IDH1 IDH2 NF1
44 myeloma, multiple 9.7 IDH1 IDH2
45 glioma 9.5 FGFR1 IDH1 IDH2 NF1
46 glioblastoma 9.5 FGFR1 IDH1 IDH2 NF1

Graphical network of the top 20 diseases related to Adult Oligodendroglioma:



Diseases related to Adult Oligodendroglioma

Symptoms & Phenotypes for Adult Oligodendroglioma

UMLS symptoms related to Adult Oligodendroglioma:


seizures, headache

Drugs & Therapeutics for Adult Oligodendroglioma

Drugs for Adult Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
4
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
5
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
8 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
9 Alkylating Agents Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
12 Antimitotic Agents Phase 2, Phase 3,Phase 1
13 Cola Phase 3,Phase 1
14 Central Nervous System Depressants Phase 3,Phase 2
15 Adjuvants, Anesthesia Phase 3
16 Liver Extracts Phase 3,Phase 2,Phase 1
17 Anesthetics, Intravenous Phase 3
18 Analgesics, Opioid Phase 3
19 Peripheral Nervous System Agents Phase 3,Phase 2
20 Anesthetics, General Phase 3
21 Analgesics Phase 3,Phase 2
22 Narcotics Phase 3
23 Anesthetics Phase 3
24 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
25 Nootropic Agents Phase 3,Phase 2
26 Cholinergic Agents Phase 3,Phase 2
27 Cholinesterase Inhibitors Phase 3,Phase 2
28
Bevacizumab Approved, Investigational Phase 2 216974-75-3
29
Busulfan Approved, Investigational Phase 2 55-98-1 2478
30
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
31
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
32
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
33
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
34
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
35
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
36
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
37
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
38
Armodafinil Approved, Investigational Phase 2 112111-43-0
39
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
40 Piracetam Approved, Investigational Phase 2 7491-74-9
41
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
42
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
43
Tamoxifen Approved Phase 2 10540-29-1 2733526
44
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
45
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
46
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
49
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
2 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
5 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
6 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
7 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
8 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
9 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
10 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
11 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
12 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
13 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
14 Sunitinib in Treating Patients With Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
15 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
16 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
17 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
18 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
19 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
20 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
21 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
22 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
23 Carboplatin in Patients With Progressive Gliomas Completed NCT00002749 Phase 2 carboplatin
24 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
25 Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma Completed NCT00005976 Phase 2 carboplatin;pyrazoloacridine
26 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
27 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
28 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
29 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
30 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
31 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
32 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
33 Temozolomide and Radiation Therapy in Treating Patients With Gliomas Active, not recruiting NCT00114140 Phase 2 Temozolomide
34 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
35 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
36 Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme Active, not recruiting NCT00892177 Phase 2 dasatinib
37 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
38 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Terminated NCT00003472 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
39 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Terminated NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
40 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
41 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
42 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
43 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
44 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
45 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
46 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
47 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
48 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
49 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
50 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus

Search NIH Clinical Center for Adult Oligodendroglioma

Genetic Tests for Adult Oligodendroglioma

Anatomical Context for Adult Oligodendroglioma

MalaCards organs/tissues related to Adult Oligodendroglioma:

41
Brain, Bone, Liver, Spinal Cord, Cerebellum, Myeloid, Bone Marrow

Publications for Adult Oligodendroglioma

Articles related to Adult Oligodendroglioma:

# Title Authors Year
1
Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis. ( 29902567 )
2018

Variations for Adult Oligodendroglioma

Expression for Adult Oligodendroglioma

Search GEO for disease gene expression data for Adult Oligodendroglioma.

Pathways for Adult Oligodendroglioma

Pathways related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.27 IDH1 IDH2
2 11.07 IDH1 IDH2
3 10.77 FGFR1 IDH1
4
Show member pathways
9.74 IDH1 IDH2

GO Terms for Adult Oligodendroglioma

Cellular components related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxisome GO:0005777 8.62 IDH1 IDH2

Biological processes related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.37 FGFR1 NF1
2 tricarboxylic acid cycle GO:0006099 9.32 IDH1 IDH2
3 2-oxoglutarate metabolic process GO:0006103 9.26 IDH1 IDH2
4 NADP metabolic process GO:0006739 9.16 IDH1 IDH2
5 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
6 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.5 FGFR1 IDH1 IDH2
2 NAD binding GO:0051287 9.26 IDH1 IDH2
3 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.16 IDH1 IDH2
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Adult Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....